Zoryve Shortage Update: What Patients Need to Know in 2026

If you've searched online for "Zoryve shortage" or noticed your pharmacy can't fill your roflumilast prescription, you're not imagining things — and you're not alone. Many patients across the country report difficulty getting Zoryve. Here's the current status, why access remains challenging, and what you should do right now.

Is Zoryve Currently in an Official FDA Shortage?

As of 2026, Zoryve (roflumilast) cream and foam are not listed on the FDA's official drug shortage database. Arcutis Biotherapeutics continues to supply both formulations, and no manufacturing disruptions have been publicly reported. However, an official "no shortage" status doesn't mean every patient can easily get their prescription filled.

Why Do Patients Still Have Trouble Getting Zoryve?

Several factors make Zoryve access difficult in 2026, even without a formal shortage:

Limited retail pharmacy stocking. Because Zoryve is expensive and newer, many retail pharmacies don't keep it on the shelf as a standard inventory item.

Prior authorization requirements. Most insurance plans require prior approval before covering Zoryve. This can take days to weeks and often requires documentation of prior treatment failures.

High cash price. Retail prices of $950–$1,145 per 60-gram tube put Zoryve out of reach for uninsured patients without a savings program.

Step therapy requirements. Some insurance plans require patients to "fail" topical corticosteroids before they'll approve Zoryve.

No generic alternative. Zoryve cream and foam are brand-name-only as of 2026, which limits price competition.

A Brief History of Zoryve: Rapid FDA Approvals Since 2022

Zoryve has been on a rapid approval trajectory since its first launch in 2022. Here's the timeline:

July 2022: Zoryve cream 0.3% approved for plaque psoriasis in patients 12 and older.

2023: Zoryve foam 0.3% approved for seborrheic dermatitis (age 9+) — the first new mechanism for seb derm in over 20 years.

2024: Zoryve cream 0.15% approved for mild to moderate atopic dermatitis (age 6+).

2025: Zoryve cream 0.05% approved for atopic dermatitis in children ages 2–5. Cream 0.3% indication extended to plaque psoriasis in children age 2+.

2025: Zoryve cream 0.15% was strongly recommended by the American Academy of Dermatology's 2025 guidelines for adults with mild to moderate atopic dermatitis.

What Should Patients Do Right Now?

If you're having trouble filling a Zoryve prescription, here's your action plan:

Call multiple pharmacies. Many retail pharmacies don't stock Zoryve, but specialty pharmacies usually do. Or use medfinder — we call pharmacies for you.

Check your PA status. If your insurer requires prior authorization, contact your dermatologist's office to confirm it was submitted and follow up.

Apply for a savings program. The ZORYVE Direct Savings Card (zoryve.com) can bring copays as low as $0 for eligible commercially insured patients. Arcutis Cares (arcutiscares.com) helps uninsured or underinsured patients get Zoryve at no cost.

Ask about alternatives. If you simply cannot get Zoryve, talk to your dermatologist about Vtama (tapinarof), Opzelura (ruxolitinib), Eucrisa (crisaborole), or topical steroids as interim options.

38,004+ patients found their medications in stock

38K+

Find Zoryve In Stock Today →

How medfinder Can Help

medfinder is a service that calls pharmacies near you to check which ones can fill your Zoryve prescription. You provide your medication details and location, and we text you the results. Visit medfinder.com to get started, or read our full guide on how to find Zoryve in stock near you.